Nuvalent (NUVL) is trading higher as investors react to fresh AACR 2026 disclosures around zidesamtinib, the company’s investigational ROS1-selective inhibitor. The April 17, 2026 release emphasized clinical activity in a difficult-to-treat subset of ROS1-positive non-small cell lung cancer patients previously treated with newer ROS1 TKIs, with notable intracranial responses highlighted for patients with CNS disease, alongside supportive preclinical brain-penetrance findings. �citeturn3view0

Beyond the incremental dataset, the update keeps focus on Nuvalent’s nearer-term regulatory path: the company reiterated that the FDA has accepted the New Drug Application for zidesamtinib and set a PDUFA target action date of September 18, 2026, positioning the program for a potential U.S. commercial launch in 2026 if approved. That combination—new efficacy/safety characterization plus a visible FDA clock—often acts as a catalyst for biotech shares when investors are looking for confirmation that a late-stage asset can differentiate in real-world-like settings such as CNS metastases and resistance mutations. �citeturn3view0

Near-term attention shifts to Nuvalent’s AACR poster sessions scheduled for April 21, 2026 in San Diego, where the company is slated to present the zidesamtinib clinical subset analysis and late-breaking preclinical work referenced in the April 17 announcement. Investors will also continue to track the broader 2026 regulatory cadence, including the September 18, 2026 PDUFA date for zidesamtinib. �citeturn3view0
�citeturn2view2